help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Endocrinology, doi:10.1210/en.2005-0606
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
147/3/1175    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Watson, C. S.
Right arrow Articles by Han, V. K. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Watson, C. S.
Right arrow Articles by Han, V. K. M.
Endocrinology Vol. 147, No. 3 1175-1186
Copyright © 2006 by The Endocrine Society

Elevated Circulating Insulin-Like Growth Factor Binding Protein-1 Is Sufficient to Cause Fetal Growth Restriction

Carole S. Watson, Peter Bialek, Makoto Anzo, Javad Khosravi, Siu-Pok Yee and Victor K. M. Han

Canadian Institutes of Health Research Group in Fetal and Neonatal Health and Development (C.S.W., V.K.M.H.), Departments of Pediatrics, Obstetrics and Gynecology and Biochemistry, University of Western Ontario, Children’s Health Research Institute, London, Ontario, Canada, N6C 2V5; London Regional Cancer Program (P.B., S.-P.Y.), University of Western Ontario, London, Ontario, Canada, N6A 4L6; Division of Pediatric Endocrinology (M.A.), David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California 90095; and Diagnostic Systems Laboratories (Canada) Inc. (J.K.), Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto and Mount Sinai Hospital, Toronto, Ontario, Canada, M5G 1X5

Address all correspondence and requests for reprints to: Dr. Carole S. Watson, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario, Canada M5G 1X5. E-mail: watson{at}mshri.on.ca.

IGF binding protein-1 (IGFBP-1) inhibits the mitogenic actions of the IGFs. Circulating IGFBP-1 is elevated in newborns and experimental animals with fetal growth restriction (FGR). To establish a causal relationship between high circulating IGFBP-1 and FGR, we have generated transgenic mice using the mouse {alpha}-fetoprotein gene promoter to target overexpression of human IGFBP-1 (hIGFBP-1) in the fetal liver. These transgenic mice (AFP-BP1) expressed hIGFBP-1 mainly in the fetal hepatocytes, starting at embryonic d 14.5 (E14.5), with lower levels in the gut. The expression peaked at 1 wk postnatally (plasma concentration, 474 ± 34 ng/ml). At birth, AFP-BP1 pups were 18% smaller [weighed 1.34 ± 0.02 g compared with 1.62 ± 0.04 g for wild type (WT); P < 0.05], and they did not demonstrate any postnatal catch-up growth. The placentas of the AFP-BP1 mice were larger than WT from E16.5 onwards (150 ± 12 for AFP-BP1 vs. 100 ± 5 mg for WT at E16.5; P < 0.05). Thus, this model of FGR is associated with a larger placenta, but without postnatal catch-up growth. Overall, these data clearly demonstrate that high concentrations of circulating IGFBP-1 are sufficient to cause FGR.




This article has been cited by other articles:


Home page
Cancer Res.Home page
N. Kobayashi, R. J. Barnard, J. Said, J. Hong-Gonzalez, D. M. Corman, M. Ku, N. B. Doan, D. Gui, D. Elashoff, P. Cohen, et al.
Effect of Low-Fat Diet on Development of Prostate Cancer and Akt Phosphorylation in the Hi-Myc Transgenic Mouse Model
Cancer Res., April 15, 2008; 68(8): 3066 - 3073.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
A. Ganguly, R. A. McKnight, S. Raychaudhuri, B.-C. Shin, Z. Ma, K. Moley, and S. U. Devaskar
Glucose transporter isoform-3 mutations cause early pregnancy loss and fetal growth restriction
Am J Physiol Endocrinol Metab, May 1, 2007; 292(5): E1241 - E1255.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
M. E Street, P. Seghini, S. Fieni, M. A. Ziveri, C. Volta, D. Martorana, I. Viani, D. Gramellini, and S. Bernasconi
Changes in interleukin-6 and IGF system and their relationships in placenta and cord blood in newborns with fetal growth restriction compared with controls.
Eur. J. Endocrinol., October 1, 2006; 155(4): 567 - 574.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
N. Ben Lagha, D. Seurin, Y. Le Bouc, M. Binoux, A. Berdal, P. Menuelle, and S. Babajko
Insulin-Like Growth Factor Binding Protein (IGFBP-1) Involvement in Intrauterine Growth Retardation: Study on IGFBP-1 Overexpressing Transgenic Mice
Endocrinology, October 1, 2006; 147(10): 4730 - 4737.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2006 by The Endocrine Society